HR 7430 117th Congress House Foreign Trade and International Finance Asia Cardiovascular and respiratory health China Competitiveness, trade promotion, trade deficits Congressional oversight Emergency medical services and trauma care Employee performance Europe Federal officials Foreign aid and international relief Government ethics and transparency, public corruption Government information and archives Government studies and investigations Health care coverage and access Health technology, devices, supplies Immunology and vaccination Infectious and parasitic diseases Intellectual property Legislative rules and procedure

Protecting American Innovation Act

Introduced: April 6, 2022 Introduced by: Smith, Adrian Republican · Nebraska See on congress.gov

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Apr 6, 2022

Referred to the Committee on Ways and Means, and in addition to the Committee on Rules, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Apr 6, 2022

Introduced in House

Plain-English summary Congressional Research Service

Protecting American Innovation Act

This bill establishes certain limitations on modifying trade agreements, including those related to the TRIPS Agreement (i.e., the Agreement on Trade-Related Aspects of Intellectual Property Rights). The TRIPS Agreement contains obligations for World Trade Organization members to protect patents and other intellectual property rights.

Specifically, the bill prohibits the President (or any U.S. official, employee, or agent) from negotiating or concluding any withdrawal, suspension, or modification to a trade agreement that adversely affects the rights of the United States or U.S. persons under a trade agreement with China or Russia.

Additionally, the bill states that a TRIPS waiver to address the COVID-19 pandemic shall not take effect if (1) the President does not submit required reports from the Department of Commerce and the Department of Defense (DOD), (2) the Commerce report concludes that the TRIPS waiver will not result in an increase in global vaccine access, or (3) the DOD report concludes that the TRIPS waiver would adversely impact U.S. national security.

Prior to entering into a negotiation with a trading partner concerning a suspension of or modification to a trade agreement, the bill requires (1) the U.S. Trade Representative to publish certain information in the Federal Register and allow for public comment, and (2) the President to provide written notice and consult with Congress. Further, the President shall not enter into any suspension of or modification to a trade agreement unless the President has complied with such consultation requirements and receives congressional approval.

What's happening now April 6, 2022

Committees of jurisdiction 2